drugset / Trial / NCT07800871
FT839 in Autoimmune Diseases
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The primary objectives of this trial are to evaluate the safety and tolerability and to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose of FT839 with or without rituximab and/or background therapy and/or conditioning therapy.
Timeline
- Start
- 2026-10
- Primary completion
- 2028-10
- Completion
- 2040-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | FT839 | Cell therapy | — | Intravenous |